LLY

1,023.96

+0.31%↑

JNJ

196.01

+0.34%↑

ABBV

232.37

0%↓

UNH

321.37

-3.25%↓

AZN

89.14

+0.64%↑

LLY

1,023.96

+0.31%↑

JNJ

196.01

+0.34%↑

ABBV

232.37

0%↓

UNH

321.37

-3.25%↓

AZN

89.14

+0.64%↑

LLY

1,023.96

+0.31%↑

JNJ

196.01

+0.34%↑

ABBV

232.37

0%↓

UNH

321.37

-3.25%↓

AZN

89.14

+0.64%↑

LLY

1,023.96

+0.31%↑

JNJ

196.01

+0.34%↑

ABBV

232.37

0%↓

UNH

321.37

-3.25%↓

AZN

89.14

+0.64%↑

LLY

1,023.96

+0.31%↑

JNJ

196.01

+0.34%↑

ABBV

232.37

0%↓

UNH

321.37

-3.25%↓

AZN

89.14

+0.64%↑

Home・Aandelen Lijst・Lisata Therapeutics

L
Lisata Therapeutics

Gesloten

2.12 6.53

Buy Sell

Overzicht

Wijziging aandelenprijs

24u

Huidig

Min

2.06

Max

2.12

Belangrijke statistieken
By Trading Economics
Werknemers	26

Aanbevelingen
By TipRanks
Aanbevelingen	Buy
12 Maanden Prognose	+624.64% upside

Marktinformatie
By TradingEconomics
Marktkapitalisatie	-1.5M 19M
Vorige openingsprijs	-4.41
Vorige sluitingsprijs	2.12

Lisata Therapeutics Grafiek

Eerdere prestaties zijn geen betrouwbare indicator voor toekomstige resultaten.

Gerelateerd nieuws

14 nov 2025, 17:45 UTC

Winsten

Belangrijke Marktbewegers

Figure Technology Shares Rise After Higher 3Q Earnings, Revenue

14 nov 2025, 17:31 UTC

Winsten

Belangrijke Marktbewegers

American Bitcoin Advances on 3Q Profit, Eric Trump's Crypto Confidence

14 nov 2025, 16:15 UTC

Belangrijke Marktbewegers

Scholar Rock Shares Rise on Renewed Apitegromab Hopes

14 nov 2025, 23:56 UTC

Acquisities, Fusies, Overnames

Berkshire Hathaway Bought Alphabet Shares Worth $4.3 Billion in the Third Quarter. Here's What It Sold. -- Barrons.com

14 nov 2025, 23:02 UTC

Marktinformatie

Chinese Battery Makers Benefit From U.S. Rising Demand -- Market Talk

14 nov 2025, 22:35 UTC

Winsten

Acquisities, Fusies, Overnames

The Score: Tyson, Robinhood, Walmart, Paramount Skydance and More Stocks That Defined the Week -- WSJ

14 nov 2025, 22:32 UTC

Acquisities, Fusies, Overnames

Berkshire Buys Shares of Alphabet and Further Pares Apple Stake -- 2nd Update

14 nov 2025, 22:29 UTC

Winsten

Starbucks Scores on Holiday Sales. It's a Good Sign for the Turnaround. -- Barrons.com

14 nov 2025, 22:00 UTC

Acquisities, Fusies, Overnames

Berkshire Buys Shares of Alphabet and Further Pares Apple Stake -- Update

14 nov 2025, 21:50 UTC

Marktinformatie

Winsten

Tech, Media & Telecom Roundup: Market Talk

14 nov 2025, 21:18 UTC

Acquisities, Fusies, Overnames

Berkshire Buys Shares of Alphabet and Pares Apple Stake -- WSJ

14 nov 2025, 20:27 UTC

Marktinformatie

Oil Futures Rise After Ukraine Strikes Russian Port -- Market Talk

14 nov 2025, 20:23 UTC

Marktinformatie

U.S. Natural Gas Futures Post Weekly Gain -- Market Talk

14 nov 2025, 20:17 UTC

Acquisities, Fusies, Overnames

Several State Attorneys General Oppose Railroad Merger -- WSJ

14 nov 2025, 19:29 UTC

Marktinformatie

Winsten

Applied Materials' F4Q Results Seen as 'Uninspiring' -- Market Talk

14 nov 2025, 18:44 UTC

Marktinformatie

Winsten

Disney's Growth Now Hinges More on ESPN -- Market Talk

14 nov 2025, 18:27 UTC

Marktinformatie

Global Equities Roundup: Market Talk

14 nov 2025, 18:27 UTC

Marktinformatie

Morgan Stanley Sees 'Worthy Successor' in Walmart CEO Furner -- Market Talk

14 nov 2025, 18:20 UTC

Marktinformatie

U.S. Oil Rig Count Rises by 3 to 417 -- Market Talk

14 nov 2025, 17:20 UTC

Marktinformatie

Winsten

Auto & Transport Roundup: Market Talk

14 nov 2025, 17:20 UTC

Marktinformatie

Acquisities, Fusies, Overnames

Health Care Roundup: Market Talk

14 nov 2025, 17:15 UTC

Marktinformatie

Global Commodities Roundup: Market Talk

14 nov 2025, 16:51 UTC

Marktinformatie

Starbucks Gets Holiday Sales Lift -- Market Talk

14 nov 2025, 16:48 UTC

Marktinformatie

Gold Slides Amid Selloff, Lower December Fed Rate-Cut Expectations -- Market Talk

14 nov 2025, 16:38 UTC

Marktinformatie

Unica Reports Higher Brazilian Sugar and Ethanol Production -- Market Talk

14 nov 2025, 16:30 UTC

Acquisities, Fusies, Overnames

Merck Is Paying Up for Flu Biotech as M&A Spree Continues -- Barrons.com

14 nov 2025, 16:28 UTC

Marktinformatie

Ukraine Strike on Russian Port Lifts Distillates -- Market Talk

14 nov 2025, 15:59 UTC

Marktinformatie

U.S. Natural Gas Inventories Rise More Than Expected -- Market Talk

14 nov 2025, 15:06 UTC

Marktinformatie

Global Forex and Fixed Income Roundup: Market Talk

14 nov 2025, 15:06 UTC

Marktinformatie

Dollar Could Benefit From U.K., French Fiscal Concerns -- Market Talk

Peer Vergelijking

Prijswijziging

Lisata Therapeutics Prognose

Koersdoel

By TipRanks

624.64% opwaarts potentieel

12 Maanden Prognose

Gemiddelde 15 USD 624.64%

Hoogste 15 USD

Laagste 15 USD

Gebaseerd op 1 Wall Street-analisten die 12-maands prijsdoelen bieden voor Lisata Therapeutics - Dist. in de afgelopen 3 maanden.

Beoordelingsconsensus

By TipRanks

Buy

1 ratings

Buy

Hold

Sell

Gebaseerd op 1 analisten die aandelenratings hebben gegeven aan Lisata Therapeutics - Dist in de afgelopen 3 maanden.

Financieel

Over Lisata Therapeutics

Lisata Therapeutics, Inc., a clinical-stage pharmaceutical company, focuses on the discovery, development, and commercialization of innovative therapies for the treatment of solid tumors and other diseases. Its product candidates include LSTA1, which is in Phase 2a and 2b clinical studies for the treatment of solid tumor, including metastatic pancreatic ductal adenocarcinoma (mPDAC), in combination with a range of anti-cancer regimens; XOWNA that is in Phase IIa clinical trial for the treatment of coronary microvascular dysfunction; and CD34+ cell therapy for the treatment of chronic kidney disease. Lisata Therapeutics, Inc. was incorporated in 1980 and is headquartered in Basking Ridge, New Jersey.